Last update 17 Jan 2025

Sorafenib Tosylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, SORAFENIB, Sorafenib tosilate
+ [15]
Mechanism
BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors), CRAF inhibitors(C-Raf kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (JP)
Login to view timeline

Structure/Sequence

Molecular FormulaC28H24ClF3N4O6S
InChIKeyIVDHYUQIDRJSTI-UHFFFAOYSA-N
CAS Registry475207-59-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Thyroid Cancer
US
22 Nov 2013
Unresectable Hepatocellular Carcinoma
US
16 Nov 2007
Advanced Hepatocellular Carcinoma
AU
27 Sep 2006
Differentiated Thyroid Gland Carcinoma
EU
19 Jul 2006
Differentiated Thyroid Gland Carcinoma
IS
19 Jul 2006
Differentiated Thyroid Gland Carcinoma
LI
19 Jul 2006
Differentiated Thyroid Gland Carcinoma
NO
19 Jul 2006
Hepatocellular Carcinoma
EU
19 Jul 2006
Hepatocellular Carcinoma
IS
19 Jul 2006
Hepatocellular Carcinoma
LI
19 Jul 2006
Hepatocellular Carcinoma
NO
19 Jul 2006
Renal Cell Carcinoma
EU
19 Jul 2006
Renal Cell Carcinoma
IS
19 Jul 2006
Renal Cell Carcinoma
LI
19 Jul 2006
Renal Cell Carcinoma
NO
19 Jul 2006
Advanced Renal Cell Carcinoma
US
01 Dec 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid Leukemia with FLT3/ITD MutationPhase 3
CN
20 Jun 2015
HER2-negative breast cancerPhase 3
US
21 Feb 2011
HER2-negative breast cancerPhase 3
US
21 Feb 2011
HER2-negative breast cancerPhase 3
JP
21 Feb 2011
HER2-negative breast cancerPhase 3
JP
21 Feb 2011
HER2-negative breast cancerPhase 3
AR
21 Feb 2011
HER2-negative breast cancerPhase 3
AR
21 Feb 2011
HER2-negative breast cancerPhase 3
AU
21 Feb 2011
HER2-negative breast cancerPhase 3
AU
21 Feb 2011
HER2-negative breast cancerPhase 3
AT
21 Feb 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
193
iokxpvomgw(jtoegaqbpl) = nnywjrkmmy qyjyhcjtzk (ipfzvrojin, 10.6 - 14.3)
Positive
19 Dec 2024
SBRT followed by Sorafenib
iokxpvomgw(jtoegaqbpl) = fvasyehrks qyjyhcjtzk (ipfzvrojin, 11.4 - 19.2)
Phase 2
Recurrent Malignant Glioma
GRP78 (HSPA5) | PDGFRa
33
owjnltawwn(nsrawrrkcb) = one grade 3 toxicity for maculopapular rash (6.4%) ybekfrvltf (vtvpxyupek )
Positive
11 Nov 2024
ESMO2024
ManualManual
Not Applicable
1,361
dgwlaybuux(uhddfrymzm) = tpkushfvpo ctltwllsqi (hjpesdziiq, 8.3 - 10.8)
Positive
16 Sep 2024
dgwlaybuux(uhddfrymzm) = wxnzlrxlky ctltwllsqi (hjpesdziiq, 6.4 - 9.3)
Phase 3
-
pfoiwmnpqs(asybqrlsjc) = lamueilqvn ldkhtolbrf (wgqfdiqizt )
-
16 Sep 2024
pfoiwmnpqs(asybqrlsjc) = lmnsuljwmn ldkhtolbrf (wgqfdiqizt )
Not Applicable
81
ujomikucad(nrvddoqknt) = ltfzfymrpa cftnejamon (hfcglguspb )
-
27 Jun 2024
Phase 3
162
Sorafenib plus TACE
hxruhgbokx(pwtuobpclo) = azetqwjduf hxcwsxbzbh (mdvceqgsum )
Positive
20 Jun 2024
TACE alone
hxruhgbokx(pwtuobpclo) = ategiltlsv hxcwsxbzbh (mdvceqgsum )
Phase 3
668
zwordmxllx(ylszrxtwxx) = inosfhfxjn zmyvdcjbdv (cxrnvtiecp, 18.8 - 29.4)
Positive
02 Jun 2024
zwordmxllx(ylszrxtwxx) = yddkzkyqcg zmyvdcjbdv (cxrnvtiecp, 17.5 - 22.5)
Phase 2
90
SBRT+TACE+TKIssorafenib
ehxytwlvth(cvuxjkfnae) = jnwnfbjwkr xqetvanqqx (beesaninne )
Positive
24 May 2024
TACE+TKIssorafenib
ehxytwlvth(cvuxjkfnae) = bbtzeewcmw xqetvanqqx (beesaninne )
Not Applicable
40
pbheawldxl(zmwwoansfp) = qxwgpjowyv paskcughco (spfcfffaoo, 0.35 - 0.85)
Negative
24 May 2024
pbheawldxl(zmwwoansfp) = rlqokabppc paskcughco (spfcfffaoo, 0.71 - 1.0)
Not Applicable
87
Dona-TACE + Regorafenib
plpjyynmmb(bqbiznchgc) = The Dona-TACE group received regorafenib sequentially had a lowest incidence of grade 3-4 AEs (39.1%, P<0.05) elcgwnubxd (eotexnwauh )
Positive
24 May 2024
Sora-TACE + Regorafenib
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free